Alexa
  • Directory of Taiwan

Amylin sues Eli Lilly over drug development deal

Amylin sues Eli Lilly over drug development deal

Amylin Pharmaceuticals is suing Eli Lilly, accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.
Amylin says Lilly is engaging in anticompetitive behavior by planning to develop and sell Boehringer's linagliptin, a treatment for adults with type 2 diabetes. Amylin and Lilly entered an agreement in 2002 to develop and sell the type 2 diabetes treatment Byetta.
The two companies also are seeking regulatory approval for a longer-lasting version of Byetta called Bydureon.
Amylin of San Diego says it plans to continue working with Lilly, but it wants to keep Lilly from using the same sales force to sell both Byetta and linagliptin.
Officials at Indianapolis-based Lilly weren't immediately available for comment.


Updated : 2021-05-18 05:27 GMT+08:00